Article | July 20, 2022

Representation In Clinical Research: Clinician Insights Re Diversity And Inclusion

Source: Trialbee AB

By Nanette K. Wenger, MD, MACC, MACP, FAHA

Diversity GettyImages-1299265628

The lack of demographic representation in clinical trials is long-felt and well-known challenge for the research community. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are putting pressure on the industry to make trials more representative of the real world population. While this is helpful, the FDA’s recent guidance[1] for industry on the topic remains just that – guidance. This means that researchers can still choose not to follow these guidelines with little to no consequence.

In the United States many communities of patients are under-represented. For some examples, whites make up roughly two-thirds (67%) of the overall U.S. population, but account for 83% of research study participants.[2] Compare that to African Americans who make up 13.4% of the U.S. population and 5% of study participants and Hispanic populations who comprise 18.1% of U.S. residents yet make up less than 1% of clinical trial participants.[3] Women are nearly twice as likely as men to experience adverse drug effects,[4] a problem linked to the fact that not enough women are participating in clinical trials, leading to a lack of insights into how therapies will uniquely affect women.[5]


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader